β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells

β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells

The clinical utilization of fenbendazole (FBZ) as a potential anticancer drug has been limited due to its low water solubility, which causes its low bioavailability. The development of a drug nanoformulation that includes the solubilizing agent as a drug carrier can improve solubility and bioavailab...

Full description

Bibliographic Details
Main Authors: Maedeh Koohi Moftakhari Esfahani, Seyed Ebrahim Alavi, Peter J. Cabot, Nazrul Islam, Emad L. Izake
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceutics
Subjects:
anthelmintic
fenbendazole
mesoporous silica nanoparticle
prostate cancer
Online Access:https://www.mdpi.com/1999-4923/14/4/884

Similar Items

Similar Items